ImmuPharma (LON:IMM) Shares Up 25.3% - Should You Buy?

Key Points

• ImmuPharma's share price increased by 25.3% during mid-day trading, reaching a last trade of GBX 17.51 ($0.24), up from GBX 13.98 ($0.19).
• The company has a market capitalization of £87.51 million and a dramatically high P/E ratio of -1,967.53, indicating it is currently not profitable.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program Lupuzor™ targeting the treatment of Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) shot up 25.3% on Monday . The stock traded as high as GBX 19.35 ($0.26) and last traded at GBX 17.51 ($0.24). 65,638,188 shares were traded during trading, an increase of 677% from the average session volume of 8,446,959 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Stock Down 15.3%

The stock has a fifty day moving average price of GBX 3.68 and a two-hundred day moving average price of GBX 3.09. The company has a market cap of £74.46 million, a price-to-earnings ratio of -1,674.16 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.